Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 1 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).
ALNY (@Biotechnology) experienced а -1.29% price change this week, while MRNA (@Biotechnology) price change was +0.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.60%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +1242.63%.
ALNY is expected to report earnings on Jul 31, 2024.
MRNA is expected to report earnings on Aug 01, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ALNY | MRNA | ALNY / MRNA | |
Capitalization | 18.4B | 40B | 46% |
EBITDA | N/A | N/A | - |
Gain YTD | -23.834 | 5.038 | -473% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
ALNY | ||
---|---|---|
OUTLOOK RATING 1..100 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 49 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 78 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALNY | MRNA | |
---|---|---|
RSI ODDS (%) | N/A | N/A |
Stochastic ODDS (%) | 1 day ago73% | 1 day ago82% |
Momentum ODDS (%) | 1 day ago79% | 1 day ago85% |
MACD ODDS (%) | 1 day ago80% | 1 day ago76% |
TrendWeek ODDS (%) | 1 day ago71% | 1 day ago81% |
TrendMonth ODDS (%) | 1 day ago68% | 1 day ago83% |
Advances ODDS (%) | N/A | 30 days ago82% |
Declines ODDS (%) | 5 days ago69% | 5 days ago83% |
BollingerBands ODDS (%) | 1 day ago76% | N/A |
Aroon ODDS (%) | 1 day ago64% | 1 day ago81% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GEBIX | 9.26 | 0.13 | +1.42% |
Goldman Sachs ESG Em Mkts Eq Inst | |||
PSBMX | 24.07 | 0.24 | +1.01% |
Principal SmallCap R3 | |||
BSMKX | 15.22 | 0.15 | +1.00% |
iShares Russell Small/Mid-Cap Idx K | |||
FCASX | 26.11 | 0.18 | +0.69% |
Fidelity Advisor Asset Manager 70% C | |||
BGRSX | 16.06 | 0.06 | +0.37% |
Boston Partners Global Long/Short Inv |
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with OCGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then OCGN could also see price increases.
Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
---|---|---|---|---|
ALNY | 100% | +0.96% | ||
OCGN - ALNY | 49% Loosely correlated | -6.06% | ||
IONS - ALNY | 46% Loosely correlated | +0.96% | ||
ATRA - ALNY | 44% Loosely correlated | +5.51% | ||
NTLA - ALNY | 43% Loosely correlated | +1.21% | ||
SGMO - ALNY | 42% Loosely correlated | -0.27% | ||
More |
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.
Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
---|---|---|---|---|
MRNA | 100% | +3.01% | ||
BNTX - MRNA | 65% Loosely correlated | +1.38% | ||
ABCL - MRNA | 40% Loosely correlated | +3.62% | ||
BEAM - MRNA | 40% Loosely correlated | +0.84% | ||
NRIX - MRNA | 40% Loosely correlated | -0.07% | ||
NTLA - MRNA | 38% Loosely correlated | +1.21% | ||
More |